Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Backs Eylea's Prospects Despite Lucentis Biosimilars

Market leader In Wet AMD Still Selling Strongly

Executive Summary

Competition, both branded and generic, is on the rise but the German group believes that Eylea will continue to outperform given its safety and efficacy profile and the potential of a longer-lasting version of the eye therapy.

You may also be interested in...



High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share

The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.

Europe’s Big Pharma Sails On Serenely Despite Choppy Economic Waters

The continent's pharmaceutical sector enjoyed another robust quarter with increased productivity, and price increases, softening the blow of rising energy costs and other challenges across the supply chain.

Viatris Tipped To Knock Out Crucial Eylea Dosing Patents In US

A senior analyst for a major investment bank has listened to oral arguments in Viatris’ legal tussle vs. Regeneron over two key US dosing patents shielding the originator’s Eylea (aflibercept) blockbuster.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel